2-(3-cyanophenyl)-4-(2-quinolinyl)-1,3-oxazole | 502422-45-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(3-cyanophenyl)-4-(2-quinolinyl)-1,3-oxazole
• 英文别名: Benzonitrile, 3-[4-(2-quinolinyl)-2-oxazolyl]-；3-(4-quinolin-2-yl-1,3-oxazol-2-yl)benzonitrile
• CAS: 502422-45-9
• 化学式: C₁₉H₁₁N₃O
• 分子量: 297.316
• InChiKey: WILMXYZSNMNDTC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  62.7
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
  申请人：——

  公开号：US20030055085A1

  公开（公告）日：2003-03-20

  The present invention provides compounds and pharmaceutical compositions that act as antagonists at metabotropic glutamate receptors, and that are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.

  本发明提供了作为代谢型谷氨酸受体拮抗剂的化合物和药物组合物，用于治疗神经系统疾病和障碍。还公开了制备这些化合物的方法。
• Treatment of neuromuscular dysfunction of the lower urinary tract with selective mGlu5 antagonists
  申请人：Recordati S.A.

  公开号：US20040215284A1

  公开（公告）日：2004-10-28

  The invention is directed to methods of using antagonists selective for the metabotropic mGlu5 receptor to treat conditions of neuromuscular dysfunction of the lower urinary tract in a mammal. Provided are methods of treating a mammal suffering from a condition of neuromuscular dysfunction of the lower urinary tract by administering a selective mGlu5 antagonist. The selective mGlu5 antagonist may be administered alone or in combination with one or more additional therapeutic agent for treating such a condition. Also provided are methods of identifying selective mGlu5 antagonists that are useful for treating neuromuscular dysfunction of the lower urinary tract in a mammal.

  本发明涉及使用选择性代谢型mGlu5受体拮抗剂治疗哺乳动物下尿路神经肌肉功能障碍的方法。本发明提供了通过施用选择性 mGlu5 拮抗剂来治疗患有下尿路神经肌肉功能障碍的哺乳动物的方法。选择性 mGlu5 拮抗剂可单独给药或与一种或多种额外的治疗剂联合给药，以治疗这种病症。还提供了鉴定选择性mGlu5拮抗剂的方法，这些选择性mGlu5拮抗剂可用于治疗哺乳动物的下尿路神经肌肉功能障碍。
• HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS
  申请人：NPS PHARMACEUTICALS, INC.

  公开号：EP1210344A1

  公开（公告）日：2002-06-05
• SELECTIVE MGLU5 ANTAGONISTS FOR TREATMENT OF NEUROMUSCULAR DYSFUNCTION OF THE LOWER URINARY TRACT
  申请人：Recordati Ireland Limited

  公开号：EP1599204A2

  公开（公告）日：2005-11-30
• NEW USE
  申请人：AstraZeneca AB

  公开号：EP1896011A1

  公开（公告）日：2008-03-12